Tafamidis meglumineProduct ingredient for Tafamidis

Show full entry for Tafamidis
Name
Tafamidis meglumine
Drug Entry
Tafamidis

Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives1 developed by FoldRX.4 Tafamidis is structurally similar to diflusinal.4

Tafamidis was granted an EMA market authorisation on 16 November 20116 and FDA approval on 3 May 2019.7

See full entry for Tafamidis
Accession Number
DBSALT002673  (DB05352)
Structure
MOLSDFPDBSMILESInChI
Similar Structures
Synonyms
D-GLUCITOL, 1-DEOXY-1-(METHYLAMINO)-, 2-(3,5-DICHLOROPHENYL)-6-BENZOXAZOLECARBOXYLATE (1:1) / D-GLUCO-2,3,4,5,6-PENTAHYDROXY-N-METHYLHEXAN-1-AMINIUM 2-(3,5-DICHLOROPHENYL)BENZOXAZOLE-6-CARBOXYLATE / Tafamidis meglumine
External IDs
FX-1006A / FX1006A